Fulcrum Therapeutics (FULC) Set to Announce Quarterly Earnings on Wednesday

Fulcrum Therapeutics (NASDAQ:FULC) is scheduled to be issuing its quarterly earnings data before the market opens on Wednesday, July 31st. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.01. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative return on equity of 40.60%. On average, analysts expect Fulcrum Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fulcrum Therapeutics Price Performance

FULC stock remained flat at $8.43 during trading on Tuesday. 122,985 shares of the company traded hands, compared to its average volume of 699,351. Fulcrum Therapeutics has a 52 week low of $3.14 and a 52 week high of $13.70. The firm has a 50-day moving average of $7.45 and a 200 day moving average of $8.18.

Wall Street Analyst Weigh In

Several research firms recently commented on FULC. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $23.00 price target on shares of Fulcrum Therapeutics in a research note on Wednesday, July 10th. Oppenheimer reduced their price target on shares of Fulcrum Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Tuesday, May 14th. The Goldman Sachs Group upgraded shares of Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $6.00 to $15.00 in a report on Monday, May 13th. Finally, HC Wainwright restated a “buy” rating and issued a $17.00 price target on shares of Fulcrum Therapeutics in a report on Tuesday, May 14th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $15.57.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.